Fetal Support Tissue Composition for Inhibiting Epithelial Cell Proliferation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods fail to effectively prevent or reduce the proliferation, cell migration, and epithelial-mesenchymal transition (EMT) of epithelial cells, particularly in conditions like proliferative vitreoretinopathy (PVR), without the need for surgical transplantation and are not suitable for non-surface epithelial cells such as retinal and renal cells.

Innovation Solution

Administration of a therapeutically effective amount of a composition comprising fetal support tissue, such as placenta or amniotic membrane extracts, combined with a pharmaceutically acceptable diluent, excipient, or carrier, which includes high molecular weight hyaluronan cross-linked with inter-α-trypsin inhibitor and pentraxin 3, to inhibit the activity of growth factors and cytokines that induce cell proliferation and EMT.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If surgical transplantation is used to treat epithelial cell proliferation and EMT, then therapeutic effectiveness is improved, but procedure complexity and invasiveness increase

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidprocedure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces surgical transplantation (mechanical intervention) with a pharmacological composition containing fetal support tissue extracts and specific proteins (HC-HA/PTX3, TSG-6, TSP-1) that inhibit epithelial cell proliferation and EMT through biochemical mechanisms, thereby eliminating the need for invasive surgical procedures while maintaining therapeutic effectiveness

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces intermediary substances (fetal support tissue extracts, HC-HA/PTX3, TSG-6, TSP-1) that mediate the therapeutic effect by binding to and inhibiting growth factors and cytokines responsible for cell proliferation and EMT, serving as molecular intermediaries between the treatment and the pathological process

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If conventional treatments are used for epithelial cell proliferation, then treatment simplicity is maintained, but effectiveness against non-surface epithelial cells is insufficient

Engineering Contradiction:

Improvetreatment simplicityVSAvoideffectiveness against non-surface epithelial cells

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent develops a universal treatment composition based on fetal support tissue extracts that effectively targets multiple types of epithelial cells including surface epithelium, retinal pigment epithelium, and other non-surface epithelial cells, making the treatment applicable across diverse tissue types and disease conditions

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent modifies the molecular parameters of the treatment by using specific proteins (HC-HA/PTX3 with molecular weight >1000 kDa, TSG-6, TSP-1) with distinct biochemical properties that enable effective interaction with various epithelial cell types and their respective growth factor receptors

Inventive Principle:

Principle #35Parameter changes

3Productivity

If growth factors and cytokines are used to promote cell proliferation, then cell regeneration is improved, but uncontrolled proliferation and EMT occur

Engineering Contradiction:

Improvecell regenerationVSAvoiduncontrolled proliferation and EMT

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of growth factors and cytokines (which cause uncontrolled proliferation and EMT) into a beneficial effect by using the same molecules in a controlled manner - the fetal support tissue extracts and specific proteins bind to these growth factors and cytokines, inhibiting their pathological activity while preserving their physiological functions for controlled cell regeneration

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS11318169B2Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells

Publication Date: 2022.05.03 TISSUE TECHNOLOGIES INC

AI summary

Compositions and preparations of fetal support tissue that prevent or reduce the proliferation and epithelial-mesenchymal transition (EMT) of epithelial cells, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or reducing the proliferation, cell migration, and EMT of epithelial cells in an individual in need thereof, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or treating proliferative vitreoretinopathy in an individual in need thereof.